Results 211 to 220 of about 190,806 (273)

Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas. [PDF]

Neuro Oncol
Schiff D, Ye X, Li J, Ellingson BM, Wen PY, Walbert T, Campian J, Nabors LB, Ozer BH, Desai A, Omuro A, Desideri S, Danda N, Grossman S, Bindra RS.   +14 more
europepmc   +1 more source

Histopathological grading affects survival in patients with isocitrate dehydrogenase-wildtype gliomas. [PDF]

Front Oncol
Hou Z, Liu D, Hou Z, Zhang H, Wang H.
europepmc   +1 more source

Corrigendum to: Single-cell profiling of peripheral and local immune compartments reveal unique genotype-independent prognostic immune signatures across isocitrate dehydrogenase-stratified glioma. [PDF]

Neuro Oncol
europepmc   +1 more source

Isocitrate dehydrogenase 1 primes group-3 medulloblastomas for cuproptosis. [PDF]

Cancer Cell
Dang D, Deogharkar A, McKolay J, Smith KS, Panwalkar P, Hoffman S, Tian W, Ji S, Azambuja AP, Natarajan SK, Lum J, Bayliss J, Manzeck K, Sweha SR, Hamanishi E, Pun M, Patel D, Rau S, Animasahun O, Achreja A, Ogrodzinski MP, Diessl J, Cotter J, Hawes D, Yang F, Doherty R, Franson AT, Hanaford AR, Eberhart CG, Raabe EH, Orr BA, Wechsler-Reya RJ, Chen B, Lyssiotis CA, Shah YM, Lunt SY, Banerjee R, Judkins AR, Prensner JR, Koschmann C, Waszak SM, Nagrath D, Simoes-Costa M, Northcott PA, Venneti S.   +44 more
europepmc   +1 more source

Isocitrate dehydrogenase 1 mutations drive downregulation of IL1R1 and dysregulated inflammatory response in acute myeloid leukemia. [PDF]

Blood Cancer J
Steinhäuser S, Beder T, Hübner E, Feuereisel DS, Jebens J, Wolgast N, Karaca MB, Richter K, Hedemann N, Steer B, Denker M, Bendig S, Brüggemann M, Silva P, Fransecky L, Neumann M, Stölzel F, Hartmann AM, Gemoll T, Bastian L, Baldus CD, Lipinski S.   +21 more
europepmc   +1 more source

Time-dependent diffusion-weighted imaging assessment of tumor grading and isocitrate dehydrogenase genotypes in adult-type diffuse gliomas. [PDF]

Jpn J Radiol
Kamimura K, Nakano T, Nakajo M, Kamizono J, Hasegawa T, Tobo D, Mukai A, Kamimura Y, Ejima F, Nagano H, Takumi K, Nakajo M, Higa N, Yonezawa H, Hanaya R, Kirishima M, Tanimoto A, Otsuka H, Hirahara D, Imai H, Feiweier T, Yoshiura T.   +21 more
europepmc   +1 more source

The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma. [PDF]

Neuro Oncol
de la Fuente MI, Touat M, van den Bent MJ, Preusser M, Peters KB, Young RJ, Huang RY, Ellingson BM, Capper D, Phillips JJ, Halasz LM, Shih HA, Rudà R, Lim-Fat MJ, Blumenthal DT, Weller M, Arakawa Y, Whittle JR, Ducray F, Reardon DA, Bi WL, Minniti G, Rahman R, Hervey-Jumper S, Chang SM, Wen PY.   +25 more
europepmc   +1 more source

Phenotype augmentation using generative AI for isocitrate dehydrogenase mutation prediction in glioma. [PDF]

Sci Rep
Jung HK, Choi C, Park JE, Park SY, Lee JH, Kim N, Kim HS.   +6 more
europepmc   +1 more source

Reliable cognitive changes the first year following guideline-based treatment of isocitrate dehydrogenase mutated gliomas: A longitudinal multicenter study. [PDF]

Neuro Oncol
Rydén I, Latini F, Alberius Munkhammar Å, Hellström P, Neimantaite A, Lycett A, Harba D, Carstam L, Blomstrand M, Zetterling M, Smits A, Jakola AS.   +11 more
europepmc   +1 more source

Predicting isocitrate dehydrogenase status in glioma using hierarchical attention-based deep 3D multiple instance learning. [PDF]

Front Oncol
Xie Q, Sun Y, Liang Y, Shang Y, Wang H, Wang F, Wei R, Chen B, Zhang M, Niu C.   +9 more
europepmc   +1 more source